- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Psychological distance.
Displaying page 1 of 1.
EudraCT Number: 2021-005383-22 | Sponsor Protocol Number: Kognition | Start Date*: 2022-07-27 |
Sponsor Name:Universitätsmedizin Göttingen | ||
Full Title: Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose) | ||
Medical condition: Iron deficiency in patients with chronic heart failure and mild cognitive impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001563-26 | Sponsor Protocol Number: NCT05355337 | Start Date*: 2022-10-03 | |||||||||||
Sponsor Name:Region Skåne | |||||||||||||
Full Title: Pramipexole for Anhedonic Depression (PRIME-PRAXOL) | |||||||||||||
Medical condition: The effect of nine weeks of treatment with the dopamine agonist Pramipexole in patients with depression with clinically significant anhedonia will be evaluated with symptom rating scales, blood and... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002407-10 | Sponsor Protocol Number: 17/0238 | Start Date*: 2018-03-23 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery. | ||||||||||||||||||
Medical condition: Obesity. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005478-29 | Sponsor Protocol Number: PTC124-GD-007-DMD | Start Date*: 2008-03-17 | ||||||||||||||||
Sponsor Name:PTC Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy | ||||||||||||||||||
Medical condition: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: FR (Completed) DE (Completed) SE (Completed) GB (Completed) BE (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004404-19 | Sponsor Protocol Number: Acadmed18013 | Start Date*: 2014-05-07 | |||||||||||
Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pul... | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004696-12 | Sponsor Protocol Number: FACIALPARALYSIS | Start Date*: 2020-01-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis | |||||||||||||
Medical condition: hemifacial paralysis (3 to 6 of the House-Brackmann scale) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001223-49 | Sponsor Protocol Number: PTC124-GD-041DMD | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension | |||||||||||||
Medical condition: Nonsense Mutation Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
